Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first emerged in
late 2019 is responsible for a pandemic of severe respiratory illness. People infected with this …

Coronavirus disease 2019 (COVID-19) represents a global crisis, yet major knowledge
gaps remain about human immunity to severe acute respiratory syndrome coronavirus 2 (SARS-…

The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of
reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and …

Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. Here, we
evaluate 254 COVID-19 patients longitudinally up to 8 months and find durable broad-based …

SARS-CoV-2, the virus responsible for COVID-19, is causing a devastating worldwide
pandemic, and there is a pressing need to understand the development, specificity, and …

To explore the human T cell response to acute viral infection, we performed a longitudinal
analysis of CD8 + T cells responding to the live yellow fever virus and smallpox vaccines—two …

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus of significant public health concern.
ZIKV shares a high degree of sequence and structural homology compared with other …

Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …